Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Cell Therapeutics (Nasdaq: CTIC) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Cell Therapeutics and see what CAPS investors are saying about the stock right now.

Cell Therapeutics facts

Headquarters (founded) Seattle (1991)
Market Cap $192.2 million
Industry Biotechnology
Trailing-12-Month EBITDA ($77.1) million
Management Co-Founder/CEO Dr. James Bianco
Co-Founder/CFO Louis Bianco
Trailing-12-Month Return on Assets (104.8%)
Cash / Debt $14.8 million / $0
Competitors Bristol-Myers Squibb
Roche Holding

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 46% of the 52 All-Star members who have rated Cell Therapeutics believe the stock will underperform the S&P 500 going forward.

Just last week, one of those Fools, zzlangerhans, tapped the stock's recent surge as particularly unsustainable:

Somehow, Cell Therapeutics has always had their coterie of rabid adherents despite the absolutely laughable loss of shareholder value over the last decade. It's like no one ever looks at the long-term price chart before buying this stock. CEO Jim Bianco continues to follow his pattern of purchasing cheap castoffs from other biotechs in order to prolong the life of his company and justify the endless cycle of capital raises and reverse splits he's become famous for. It's painful to even spend the time to review the pipeline because it's so obvious that no success will ever come from this company. Next disappointment is likely to be crappy revenues from Pixuvri in Europe.

If you want market-thumping returns, you need to protect your portfolio from any undue risk. We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.